Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression

References

• McDonagh M, Peterson K, Holzhammer B, et al. A systematic review of PCSK9 inhibitors alirocumab and evolocumab. J Manag Care Spec Pharm. 2016;22(6):641–53q.
   PubMed Web of Science ®Google Scholar
• Warden BA, Fazio S, Shapiro MD. The PCSK9 revolution: current status, controversies, and future directions. Trends Cardiovasc Med. 2020;30(3):179–185. doi:10.1016/j.tcm.2019.05.007.
   PubMed Web of Science ®Google Scholar
• Coppinger C, Movahed MR, Azemawah V, et al. A comprehensive review of PCSK9 inhibitors. J Cardiovasc Pharmacol Ther. 2022;27:10742484221100107. doi:10.1177/10742484221100107.
   Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–1509. doi:10.1056/NEJMoa1500858.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–1499. doi:10.1056/NEJMoa1501031.
   PubMed Web of Science ®Google Scholar
• Szarek M, White HD, Schwartz GG, et al. Alirocumab reduces total nonfatal cardiovascular and fatal events: the Odyssey Outcomes trial. J Am Coll Cardiol. 2019;73(4):387–396. doi:10.1016/j.jacc.2018.10.039.
   PubMed Web of Science ®Google Scholar
• Liu C, Chen J, Chen H, et al. PCSK9 inhibition: from current advances to evolving future. Cells. 2022;11(19):2972. doi:10.3390/cells11192972.
   PubMed Web of Science ®Google Scholar
• Hardy J, Niman S, Pereira E, et al. A critical review of the efficacy and safety of Inclisiran. Am J Cardiovasc Drugs. 2021;21(6):629–642. doi:10.1007/s40256-021-00477-7.
   PubMed Web of Science ®Google Scholar
• Ray KK, Troquay RPT, Visseren FLJ, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11(2):109–119. doi:10.1016/S2213-8587(22)00353-9.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Bezerra CT, Grande AJ, Galvão VK, et al. Assessment of the strength of recommendation and quality of evidence: GRADE checklist. A descriptive study. Sao Paulo Med J. 2022;140(6):829–836. doi:10.1590/1516-3180.2022.0043.R1.07042022.
   PubMed Web of Science ®Google Scholar
• Sideri S, Papageorgiou SN, Eliades T. Registration in the international prospective register of systematic reviews (PROSPERO) of systematic review protocols was associated with increased review quality. J Clin Epidemiol. 2018;100:103–110. doi:10.1016/j.jclinepi.2018.01.003.
   PubMed Web of Science ®Google Scholar
• Choi HD, Kim JH. An updated meta-analysis for safety evaluation of alirocumab and evolocumab as PCSK9 inhibitors. Cardiovasc Ther. 2023;2023:7362551–7362511. doi:10.1155/2023/7362551.
   PubMed Web of Science ®Google Scholar
• Li J, Du H, Wang Y, et al. Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis. Heart. 2022;108(16):1296–1302. doi:10.1136/heartjnl-2021-320556.
   PubMed Web of Science ®Google Scholar
• Guedeney P, Giustino G, Sorrentino S, et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2022;43(7):e17-e25. doi:10.1093/eurheartj/ehz430.
   Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722. doi:10.1056/NEJMoa1615664.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107. doi:10.1056/NEJMoa1801174.
   PubMed Web of Science ®Google Scholar
• Hovingh GK, Raal FJ, Dent R, et al. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017;11(6):1448–1457. doi:10.1016/j.jacl.2017.09.003.
   PubMed Web of Science ®Google Scholar
• Gencer B, Mach F, Murphy SA, et al. Efficacy of Evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: a prespecified secondary analysis from the FOURIER trial. JAMA Cardiol. 2020;5(8):952–957. doi:10.1001/jamacardio.2020.0882.
   PubMed Web of Science ®Google Scholar
• Frederick Berro Rivera MSWC, Paul Aparece MDJ, Rocimo MDA, et al. Sex Differences in Cardiovascular Outcomes and Cholesterol-Lowering Efficacy of PCSK9 Inhibitors: systematic Review and Meta-Analysis. USA: JACC Advances; 2023.
   Google Scholar
• Fogacci F, Yerlitaş S, Giovannini M, et al. Sex X time interactions in Lp(a) and LDL-C response to evolocumab. Biomedicines. 2023;11(12):3271. doi:10.3390/biomedicines11123271.
   PubMed Web of Science ®Google Scholar
• Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of Evolocumab in treatment of hypercholesterolemia: results Up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol. 2017;2(6):598–607. doi:10.1001/jamacardio.2017.0747.
   PubMed Web of Science ®Google Scholar
• Dufour R, Hovingh GK, Guyton JR, et al. Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: results from an open-label extension of the ODYSSEY LONG TERM trial. J Clin Lipidol. 2019;13(1):138–147.
   PubMed Web of Science ®Google Scholar
• Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term efficacy and safety of Evolocumab in patients with hypercholesterolemia. J Am Coll Cardiol. 2019;74(17):2132–2146. doi:10.1016/j.jacc.2019.08.1024.
   PubMed Web of Science ®Google Scholar
• Goodman SG, Steg PG, Poulouin Y, et al. Long-term efficacy, safety, and tolerability of alirocumab in 8242 patients eligible for 3 to 5 years of placebo-controlled observation in the Odyssey Outcomes trial. J Am Heart Assoc. 2023;12:e029216.
   PubMed Web of Science ®Google Scholar
• Gayoso-Rey M, Díaz-Trastoy O, Romero-Ventosa EY, et al. Effectiveness, safety, and adherence to treatment of proprotein convertase Subtilisin/Kexin Type 9 inhibitors in real practice. Clin Ther. 2021;43(4):e111–e21. doi:10.1016/j.clinthera.2021.02.002.
   PubMed Web of Science ®Google Scholar
• Blanco-Ruiz M, Amaya-Pascasio L, de Torres Chacón R, et al. Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study. Atheroscler Plus. 2021;45:32–38. doi:10.1016/j.athplu.2021.08.009.
   PubMedGoogle Scholar
• Hirayama A, Yamashita S, Ruzza A, et al. Long-term treatment with evolocumab among Japanese patients ― Final report of the OSLER Open-Label Extension Studies. Circ J. 2019;83(5):971–977. doi:10.1253/circj.CJ-19-0139.
   Google Scholar
• Da Dalt L, Castiglioni L, Baragetti A, et al. PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction. Eur Heart J. 2021;42(32):3078–3090. doi:10.1093/eurheartj/ehab431.
   PubMed Web of Science ®Google Scholar
• Feng Z, Li X, Tong WK, et al. Real-world safety of PCSK9 inhibitors: a pharmacovigilance study based on spontaneous reports in FAERS. Front Pharmacol. 2022;13:894685. doi:10.3389/fphar.2022.894685.
   PubMed Web of Science ®Google Scholar
• Volis I, Hislop E, Saliba W, et al. A safety and clinical efficacy analysis of PCSK9 monoclonal antibodies in patients with markedly elevated creatine phosphokinase levels. Am J Blood Res. 2021;11(4):399–404.
   PubMedGoogle Scholar
• Moghadam-Kia S, Oddis CV, Aggarwal R. Approach to asymptomatic creatine kinase elevation. Cleve Clin J Med. 2016;83(1):37–42. doi:10.3949/ccjm.83a.14120.
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–1022. doi:10.1093/eurheartj/ehv043.
   PubMed Web of Science ®Google Scholar
• Hussain A, Kaler J, Ray SD. The Benefits Outweigh the Risks of Treating Hypercholesterolemia: the Statin Dilemma. Cureus. 2023;15(1):e33648. doi:10.7759/cureus.33648.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. doi:10.1093/eurheartj/ehz455.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: executive Summary: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168–3209. doi:10.1016/j.jacc.2018.11.002.
   PubMed Web of Science ®Google Scholar
• Jones PH, Bays HE, Chaudhari U, et al. Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 randomized trials. Am J Cardiol. 2016;118(12):1805–1811. doi:10.1016/j.amjcard.2016.08.072.
   PubMed Web of Science ®Google Scholar
• Mannarino MR, Sahebkar A, Bianconi V, et al. PCSK9 and neurocognitive function: should it be still an issue after Fourier and Ebbinghaus results? J Clin Lipidol. 2018;12(5):1123–1132. doi:10.1016/j.jacl.2018.05.012.
   PubMed Web of Science ®Google Scholar
• Gencer B, Mach F, Guo J, et al. Cognition after lowering LDL-cholesterol with evolocumab. J Am Coll Cardiol. 2020;75(18):2283–2293. doi:10.1016/j.jacc.2020.03.039.
   PubMed Web of Science ®Google Scholar
• Sinnaeve PR, Schwartz GG, Wojdyla DM, et al. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an Odyssey Outcomes trial analysis. Eur Heart J. 2020;41(24):2248–2258. doi:10.1093/eurheartj/ehz809.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377(7):633–643. doi:10.1056/NEJMoa1701131.
   PubMed Web of Science ®Google Scholar
• Hirsh Raccah B, Yanovsky A, Treves N, et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: a systematic review, meta-analysis and meta-regression. Int J Cardiol. 2021;335:7–14. doi:10.1016/j.ijcard.2021.04.025.
   PubMed Web of Science ®Google Scholar
• Ying H, Wang J, Shen Z, et al. Impact of lowering low-density lipoprotein cholesterol with contemporary lipid-lowering medicines on cognitive function: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2021;35(1):153–166. doi:10.1007/s10557-020-07045-2.
   PubMed Web of Science ®Google Scholar
• Seijas-Amigo J, Mauriz-Montero MJ, Suarez-Artime P, et al. Cognitive function with PCSK9 inhibitors: a 24-month follow-up observational prospective study in the real world-Memogal study. Am J Cardiovasc Drugs. 2023;23(5):583–593. doi:10.1007/s40256-023-00604-6.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146(15):1109–1119. doi:10.1161/CIRCULATIONAHA.122.061620.
   PubMed Web of Science ®Google Scholar
• Carugo S, Sirtori CR, Corsini A, et al. PCSK9 inhibition and risk of diabetes: Should we worry? Curr Atheroscler Rep. 2022;24(12):995–1004. doi:10.1007/s11883-022-01074-y.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Ferri N, Banach M, et al. Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovasc Res. 2023;118(17):3288–3304. doi:10.1093/cvr/cvac020.
   PubMed Web of Science ®Google Scholar
• Marku A, Da Dalt L, Galli A, et al. Pancreatic PCSK9 controls the organization of the β-cell secretory pathway via LDLR-cholesterol axis. Metabolism. 2022;136:155291. doi:10.1016/j.metabol.2022.155291.
   PubMed Web of Science ®Google Scholar
• Hummelgaard S, Vilstrup JP, Gustafsen C, et al. Targeting PCSK9 to tackle cardiovascular disease. Pharmacol Ther. 2023;249:108480. doi:10.1016/j.pharmthera.2023.108480.
   PubMed Web of Science ®Google Scholar
• Ray KK, Colhoun HM, Szarek M, et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(8):618–628. doi:10.1016/S2213-8587(19)30158-5.
   PubMed Web of Science ®Google Scholar
• Kosmas CE, Skavdis A, Sourlas A, et al. Safety and tolerability of PCSK9 inhibitors: current insights. Clin Pharmacol. 2020;12:191–202. doi:10.2147/CPAA.S288831.
   PubMed Web of Science ®Google Scholar
• González-Lleó AM, Sánchez-Hernández RM, Plana N, et al. Impact of PCSK9 inhibitors in glycaemic control and new-onset diabetes. Cardiovasc Diabetol. 2024;23(1):4. doi:10.1186/s12933-023-02077-y.
   PubMed Web of Science ®Google Scholar
• Marouf BH, Iqbal Z, Mohamad JB, et al. Efficacy and safety of PCSK9 monoclonal antibodies in patients with diabetes. Clin Ther. 2022;44(2):331–348. doi:10.1016/j.clinthera.2021.12.005.
   PubMed Web of Science ®Google Scholar
• de Carvalho LSF, Campos AM, Sposito AC. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and incident type 2 diabetes: a systematic review and meta-analysis with over 96,000 patient-years. Diabetes Care. 2018;41(4):e70–e71. doi:10.2337/dc17-1464.
   PubMedGoogle Scholar
• Leiter LA, Cariou B, Müller-Wieland D, et al. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the Odyssey DM-Insulin randomized trial. Diabetes Obes Metab. 2017;19(12):1781–1792. doi:10.1111/dom.13114.
   PubMed Web of Science ®Google Scholar
• Ray KK, Leiter LA, Müller-Wieland D, et al. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: the Odyssey DM-Dyslipidemia randomized trial. Diabetes Obes Metab. 2018;20(6):1479–1489.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Daviglus ML, Handelsman Y, et al. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled Banting study. Diabetologia. 2019;62(6):948–958. doi:10.1007/s00125-019-4856-7.
   PubMed Web of Science ®Google Scholar
• Lorenzatti AJ, Eliaschewitz FG, Chen Y, et al. Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: the Berson clinical trial. Clin Cardiol. 2018;41(9):1117–1122. doi:10.1002/clc.23018.
   PubMed Web of Science ®Google Scholar
• Goldman A, Raschi E, Cukierman-Yaffe T, et al. Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study. Eur J Prev Cardiol. 2022;29(9):1334–1342. doi:10.1093/eurjpc/zwab209.
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Lepor NE. PCSK9 inhibitors in lipid management of patients with diabetes mellitus and high cardiovascular risk: a review. J Am Heart Assoc. 2018;7(13):53. doi:10.1161/JAHA.118.008953.
   Web of Science ®Google Scholar